Association of the CYP3A5 A6986G (CYP3A5*3) polymorphism with saquinavir pharmacokinetics.

  title={Association of the CYP3A5 A6986G (CYP3A5*3) polymorphism with saquinavir pharmacokinetics.},
  author={M. Fr{\"o}hlich and M. Hoffmann and J. Burhenne and G. Mikus and J. Weiss and W. Haefeli},
  journal={British journal of clinical pharmacology},
  volume={58 4},
  • M. Fröhlich, M. Hoffmann, +3 authors W. Haefeli
  • Published 2004
  • Biology, Medicine
  • British journal of clinical pharmacology
  • Saquinavir is a selective HIV protease inhibitor with limited systemic bioavailability (4% for the hard gelatin capsule (Invirase®), and about 12% for the soft gelatin capsule (Fortovase®) [1]) as a result of extensive phase I metabolism by CYP3A in the gut and liver. Moreover, saquinavir bioavailability is characterized by substantial interindividual variability [2], a feature which is common to other CYP3A substrates [3] and which could only be partly explained by drug interactions with… CONTINUE READING
    62 Citations
    CYP3A5 Genotype has an Impact on the Metabolism of the HIV Protease Inhibitor Saquinavir
    • 66
    Minimal effect of MDR1 and CYP3A5 genetic polymorphisms on the pharmacokinetics of indinavir in HIV-infected patients.
    • 38
    PharmGKB summary: very important pharmacogene information for CYP3A5.
    • 82
    Analysis of single-nucleotide polymorphisms (SNPs) in human CYP3A4 and CYP3A5 genes: potential implications for the metabolism of HIV drugs
    • 16
    • PDF
    Variation in oral clearance of saquinavir is predicted by CYP3A5*1 genotype but not by enterocyte content of cytochrome P450 3A5
    • 102
    The Effect of ABCB1 Polymorphism on the Pharmacokinetics of Saquinavir Alone and in Combination with Ritonavir
    • 16
    The Influence of CYP3A5 Genotype on Dexamethasone Induction of CYP3A Activity in African Americans
    • 28
    • PDF


    Role of P-glycoprotein and cytochrome P450 3A in limiting oral absorption of peptides and peptidomimetics.
    • 415
    Genetic contribution to variable human CYP3A-mediated metabolism.
    • 890
    Dose-dependent increase of saquinavir bioavailability by the pharmaceutic aid cremophor EL.
    • 68
    Comparative analysis of CYP3A expression in human liver suggests only a minor role for CYP3A5 in drug metabolism.
    • 252
    Reduction of Saquinavir Exposure by Coadministration of Loperamide
    • 7
    Oral contraception does not alter single dose saquinavir pharmacokinetics in women.
    • 27